Avance (2021a).NPV vs rNPV. Available at: https://avance.ch/download/npv-vs-rnpv/.
Avance (2021b). Discount rates in drug development. Available at: https://avance.ch/download/discount-rates-in-pharma-and-biotech/.
Biotechnology Innovation Organization (2021). Clinical development success rates and contributing factors 2011–2020. Informa Pharma Intelligence, QLS advisors.
Black, F. and M. Scholes (1973). The Pricing of Options and Corporate Liabilities. Journal of Political Economy, 81(3), 637–654. http://www.jstor.org/stable/1831029.
Bogdan, B. and R. Villiger (2010). Valuation in Life Sciences. 3rd edn. Berlin, Heidelberg: Springer.
Chance, D.M. and P.P. Peterson (2002). Real Options and Investment Valuation. The Research Foundation of the Association for Investment Management and Research (now Chartered Financial Analyst Institute).
Clinical Research (2019). Cost of Clinical Trials: A Breakdown (Infographic). Available at: www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trials-breakdown.
Cook, A. (2016). Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them.. 2nd edn. London: Gower.
Copeland, T. and V. Antikarov (2001). Real Options – A Practitioners’ Guide. New York: Texere.
Schlander, M. et al. (2021). How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics, 39(11), pp. 1243–1269. doi.org/10.1007/s40273-021-01065-y.